According to IFFGD and the official Congressional legislative database Congress.gov, Representative Tom Suozzi (D-NY-3) and Representative Ron Kind (D-WI-3) signed on recently as co-sponsors of the Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2017.
Representative Suozzi is serving his first term in the House of Representatives. His district, the 3rd Congressional District of New York, currently encompasses most of the North Shore of Long Island in northern Nassau and northwestern Suffolk Counties, including Huntington, Northport, Commack, Dix Hills, Plainview, Hicksville, Syosset, Glen Cove, Roslyn, Port Washington, and Great Neck, as well as a northeastern portion of the New York City borough of Queens, including the Little Neck, Whitestone, Glen Oaks, and Floral Park communities. Representative Suozzi supports a range of health and veterans’ issues and is currently a member of the Congressional caucuses and bipartisan task forces for several other specific chronic medical conditions, including the Military Mental Health Caucus as seen on his official house website. As previously discussed on this blog on August 12, 2011 and August 25, 2011, military service members and veterans are also at disproportionately high risk for functional gastrointestinal disorders like IBS, which are already very common in the general population.
Representative Kind is serving his eleventh term as a member of the House of Representatives. His district, the 3rd Congressional District of Wisconsin, represents the western part of the state, including La Crosse, Eau Claire and Platteville. According to his official House website, he is a member of the Subcommittee on Health of the House Committee of Ways and Means. He also has a record of supporting legislation of concern to veterans. Representative Kind also previously co-sponsored HR 2239 in the 112th Congress (2011-2012) and HR 842 in the 113th Congress (2013-2014), and HR 2311 in the 114th Congress (2015-2016), which did not pass. IBS Impact thanks him for his long support of the functional gastrointestinal disorders community for four consecutive Congresses since the inception of the legislative effort for this Act.
In officially supporting HR 1187, Representatives Suozzi and Kind join Representative F. James Sensenbrenner, Jr. (R-WI-5), who is the initial sponsor, and co-sponsors, Representatives Mark Pocan (D-WI-2), Eliot Engel (D-NY-16), Dave Loebsack (D-IA-2), and Alcee Hastings (D-FL-20). If you are a constituent of any of these legislators, please take a few minutes to call, write, or contact him on social media to thank him for his support of the functional gastrointestinal and motility disorders community.
U. S. citizens, if your Member of Congress is not yet a co-sponsor of HR 1187, please see the previous post from March 21, 2017 for links to the bill and more details on how to do so. Often, it takes multiple attempts to elicit any interest from legislators, so if you do not receive a reply, do not hesitate to try again or to switch contact methods until you attract attention. Keep in mind that your Representative may be different from before because of the 2016 elections, district boundaries that may have been re-drawn, or if you have moved.
Your personal experiences as a person with IBS and/or other functional GI/motility disorders, or as a concerned family member, friend or colleague, are most effective in communicating to legislators and their staff that there are real human beings behind the statistics. However, even general expressions of support are helpful.
HR 1187 is bipartisan legislation (supported by members of both parties) and according to IFFGD discussions with IBS Impact, is “revenue-neutral,” meaning that there will be no additional taxes or spending added to the current federal deficit if it is enacted. Discretionary funds are available at the National Institutes of Health to be allocated if Congress directs NIH, through this Act, that functional gastrointestinal and motility disorders are a priority. Congress will only do so if we, as a community, are able to show them the importance of the research, education and FDA coordination provided for in HR 1187.
NIH grants funding to researchers throughout the world, not just in the U.S., so in the long run, enactment of this Act may also benefit readers with IBS in other countries. Medical research also sometimes involves multinational teams of scientists, and in any case, study results are usually published globally, adding to the cumulative knowledge worldwide.
It is IBS Impact’s understanding that HR 1187 will not require a debate or vote on the floor of the House of Representatives, and will pass as soon as it reaches 218 sponsor/cosponsors, or a simple majority of the House. In order for this milestone to be accomplished during the current Congress, the 115th, the necessary number of sponsor/cosponsors must be reached by December 2018. Every two years, the Congressional membership will be different as a result of elections. Thus, if HR 1187 has not passed by that time, a similar bill will have to be reintroduced and the FGIMD community will have to start the process of gathering co-sponsors anew. This is what occurred with HR 2239 in 2012, HR 842 in 2014 and HR 2311 in 2016. While it is quite common for legislation of various sorts to take several Congresses to pass, our continuing advocacy now can increase awareness, build momentum and perhaps accelerate passage. It is in our hands.
Check back on this blog or join IBS Impact’s Facebook page or Twitter feed for further updates on HR 1187 as they occur. Links to the social media sites can be found on the right sidebar of the blog.